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Abstract
Revertant mosaicism, or “natural gene therapy”, is the phenomenon in which germline muta-
tions are corrected by somatic events. In recent years, revertant mosaicism has been identi-
fied in all major types of epidermolysis bullosa, the group of heritable blistering disorders
caused by mutations in the genes encoding epidermal adhesion proteins. Moreover, rever-
tant mosaicism appears to be present in all patients with a specific subtype of recessive
epidermolysis bullosa. We therefore hypothesized that revertant mosaicism should be
expected at least in all patients with recessive forms of epidermolysis bullosa. Naturally cor-
rected, patient-own cells are of extreme interest for their promising therapeutic potential,
and their presence in all patients would open exciting, new treatment perspectives to those
patients. To test our hypothesis, we determined the probability that single nucleotide re-
versions occur in patients’ skin using a mathematical developmental model. According to
our model, reverse mutations are expected to occur frequently (estimated 216x) in each
patient’s skin. Reverse mutations should, however, occur early in embryogenesis to be able
to drive the emergence of recognizable revertant patches, which is expected to occur in only
one per ~10,000 patients. This underestimate, compared to our clinical observations, can
be explained by the “late-but-fitter revertant cell” hypothesis: reverse mutations arise at later
stages of development, but provide revertant cells with a selective growth advantage in vivo
that drives the development of recognizable healthy skin patches. Our results can be extrap-
olated to any other organ with stem cell division numbers comparable to skin, which may
offer novel future therapeutic options for other genetic conditions if these revertant cells can
be identified and isolated.
Introduction
Revertant mosaicism (RM), or “natural gene therapy”, is the phenomenon in which the effect
of germline mutations is corrected by somatic mutational events, and hence constitutes a
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modifier of disease. RM was first reported in Lesch-Nyhan syndrome in 1988 [1], and subse-
quently in several other genetic syndromes [2,3]. In 1997, RM was first reported in a genetic
skin condition, epidermolysis bullosa (EB) [4], the group of heritable blistering disorders
caused by mutations in the genes encoding the components of the epidermal-dermal adhesion
complex [5]. While long considered an extraordinary phenomenon, RM has been identified
in all major types of EB in recent years (Table 1) [4–19]. Moreover, in a Dutch study RM ap-
peared to be present in all patients with the generalized intermediate subtype of junctional EB
(formerly: non-Herlitz junctional EB) on clinical examination, and could be proven at the
DNA level in 60% of patients with this EB type [11]. RM has also been shown to be an impor-
tant disease-modifier in ichthyosis with confetti, another genetic skin disorder, caused by
mutations in the KRT1 or KRT10 genes [20,21]. These findings have led to the conclusion that,
instead of being extraordinary, RM seems to be rather common in EB and led us to hypothe-
size that RM is present in all patients with EB. In the light of the exciting progress made on
revertant cell therapy in recent years [22], boosted especially by the combination with the
induced pluripotent stem cell approach [23], as well as the recent successful regeneration of an
entire human epidermis from exogenously corrected epidermal stem cells [24], the presence of
RM in all EB patients would have important implications for future revertant cell therapy
development. In this study, we therefore sought to obtain proof for our hypothesis by employ-
ing a mathematical developmental model of the skin. Our results indicate that revertant cells
should be present in the skin of all EB patients, but they need a significant selective growth
advantage to be able to grow out to clinically recognizable healthy skin patches.
Results and discussion
We used a simplified mathematical developmental model, in which we focused on single
nucleotide corrections of nonsense mutations in recessive types of EB (REB), the dominant
type of reversion mutations observed in EB [25]. We also focused on the probability that
reverse mutations occur until adulthood is reached, not the probability that reverse mutations
occur during adult life, because, as discussed later in more detail, the revertant patches that we
observe in EB patients develop before adulthood. In this model, the number of basal keratino-
cytes (BKs), n, starting with a single embryonic ectodermal progenitor cell, increases exponen-
tially in the epidermis, n = 2y, with each generation, y. The probability that reverse mutations
occur until adulthood then depends on four factors: (1) the total number of BKs in an adult
human body (estimated to be 36×109, ~235), (2) the number of mitoses required to obtain this
number (36×109–1), (3) the probability of a nucleotide alteration per nucleotide per mitosis
(~1×10−9) [26–28], and (4) the number of target nucleotides that are able to correct the
Table 1. Revertant mosaicism in epidermolysis bullosa.
Major EB type EB subtype OMIM Corrected gene OMIM References
EB simplex EBS, generalized severe 131760 KRT14 148066 [6]
EBS, autosomal recessive K14 601001 KRT14 148066 [7]
Junctional EB JEB, generalized intermediate (AR) 226650 COL17A1 113811 [4,8–12]
LAMB3 150310 [13]
Dystrophic EB Recessive DEB, generalized severe 226600 COL7A1 120120 [14–16]
Recessive DEB, generalized intermediate 226600 COL7A1 120120 [16,17]]
Dominant DEB 131750 COL7A1 120120 [16]
Kindler syndrome - 173650 FERMT1 607900 [18,19]
EB, epidermolysis bullosa; EBS, epidermolysis bullosa simplex; JEB, junctional epidermolysis bullosa; DEB, dystrophic epidermolysis bullosa; AR, autosomal recessive.
https://doi.org/10.1371/journal.pone.0192994.t001
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germline mutation when altered (assumed 6 in a recessive model, ignoring the possibility of a
nonsense codon being changed into one of the other two nonsense codons). See Table 2 and
Methods section at the end of this manuscript for details on the mathematical calculations and
quantitative estimates used in this study.[29–35] Our model shows that, during the total num-
ber of mitoses, the probability P that at least one reverse mutation occurs approaches 1 and
reverse mutations are expected to occur 216 times in an average adult human body. This indi-
cates that, indeed, the occurrence of reverse mutations should not be considered extraordi-
nary, but rather an event that can be expected with mathematical certainty in REB patients’
skin carrying mutations that are correctable by single nucleotide mutations. This finding cor-
responds well to the results of a recent study that demonstrated a strong correlation between
the high population incidence of basal cell carcinomas and the high number of basal stem cell
mitoses in the skin, which was attributed to stochastic events of numerous randomly occurring
somatic mutations [36].
Knowing that revertant mutations should occur frequently in the skin of patients with REB,
the next question is whether these revertant cells will be able to grow out to healthy, revertant
skin patches that are clinically recognizable. To induce recognizable patches, i.e. patches cover-
ing at least 1 cm2 (corresponding to 2×106 revertant BKs) (Fig 1) [9], reverse mutations in our
model should arise in the 14th cell generation the latest (214 = 16,384 BKs) (Methods section,
Table 2). This number of cells is supposed to be reached before the 4th week of embryogenesis
[37]. The probability P that at least one reverse mutation will have occurred in the first 14 gen-
erations is only ~0.0001. A clinically recognizable, healthy revertant skin patch should there-
fore be expected in only one per ~10,000 patients (~1/0.0001).
Evidently, this conclusion strongly contradicts our clinical observations that revertant
patches are present in all Dutch patients with generalized intermediate junctional EB [11].
This underestimate can only be partly explained by the developmental model itself. First, the
model ignores cell loss due to normal biologic processes, like apoptosis and differentiation. As
the probability that reverse mutations occur depends on the number of mitoses needed to ob-
tain final cell numbers, integrating cell loss will increase this probability by means of increasing
the total number of mitoses. To get an impression of the effect of cell loss, we next used a con-
servative model in which we assumed that 90% of new cells in each generation would be lost,
ny = 1.1y, as the exact cell loss rate is unknown. In this model 359×109 mitoses (255 genera-
tions) are required to obtain the 36×109 BKs of an adult human body; and 19.6×106 mitoses
(152 generations) are required for the 2×106 cells of a 1 cm2 recognizable revertant patch,
assuming identical growth and loss rates for mutant and revertant cells. The reverse mutation
should then occur no later than in the 103rd generation, when the absolute minimal number of
cells needed to obtain a revertant skin patch at adulthood is reached (18×103 BKs, 180×103
mitoses), which again is before the 4th week of embryonic development [37]. Loss of 90% of
cells in each generation would thus increase the required number of mitoses ~10x compared
to the initial model. The probability of recognizable patches (P = 0.0011) consequently also
increases a factor 10. Hence, even with 90% cell loss in each generation, recognizable revertant
patches could be expected in only one per ~909 patients (~1/0.0011) and cannot explain their
much more frequent clinical appearance.
Second, we assumed that all BKs are equal and need to be revertant. In reality, a hierarchy
among BKs is recognized: long-term proliferating epidermal stem cells produce clonogenic
transient amplifying cells that provide the other (transient amplifying) BKs to the epidermal
proliferating units, which collectively form skin patches [35,38]. Only a limited number of epi-
dermal stem cells thus need to be revertant in order to acquire recognizable revertant patches.
This critical number of revertant stem cells per mm2 needed for recognizable patches is
unknown, but it is undoubtedly smaller than the number used before. To estimate the possible
Mathematical dissection of revertant mosaicism
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Table 2. Quantitative estimates and calculated values in our developmental model of the skin.
Quantitative
values
Explanation References
6 complexes Average number of rete ridges-dermal papillae complexes per mm skin
length
[29]
0.070 mm Average height of rete ridges-dermal papillae complexes [30]
1.348 mm DEJ length corresponding to 1 mm of skin length Calculated in this
study
1.817 mm2 DEJ surface corresponding to 1 mm2 of skin surface Calculated in this
study
81.7% Increase in dermo-epidermal contact due to rete ridges-dermal papillae
complexes
Calculated in this
study
10 μm Diameter of circular base of basal keratinocytes [31]
20,000 cells Number of basal keratinocytes per mm2 skin Used in this study
15,000 cells Number of basal keratinocytes per mm2 skin [32]
20,000–30,000
cells
Number of basal keratinocytes per mm2 skin [33]
23,146 cells Number of basal keratinocytes per mm2 skin Calculated in this
study
1.8 m2 Average skin surface in adult human body Used in this study
3.3x106 mm2 Average total DEJ surface in adult human body Calculated in this
study
36x109 cells Average total number of basal keratinocytes in adult human body Calculated in this
study
(36x109–1)
mitoses
Number of mitoses needed to obtain total number of basal keratinocytes Calculated in this
study
35.1 generations Number of generations of cells needed to obtain total number of basal
keratinocytes
Calculated in this
study
1x10-9 Approximate per nucleotide point mutation rate per mitosis [26–28]
6x109 nucleotides Approximate number of nucleotides per genome [34]
6 mutations Expected number of novel point mutations per mitosis Calculated in this
study
216x109
mutations
Expected number of point mutations in basal keratinocytes of human
body at adulthood
Calculated in this
study
36x Average point mutation frequency of each nucleotide in basal
keratinocytes of human body at adulthood
Calculated in this
study
105 Total number of somatic mutations expected to have accumulated per BK
at adulthood
Calculated in this
study
6 nucleotides Number of target nucleotides for a reverse mutation in REB patients with
2 nonsense mutations
Calculated in this
study
6x10-9 Probability of a reverse point mutation per mitosis Calculated in this
study
1.6x10-94 Probability that no reverse mutation occurs during total (36x109–1)
mitoses (Pnot)
Calculated in this
study
~1 Probability that at least one reverse mutation occurs during total number
of mitoses (P = 1 –Pnot)
Calculated in this
study
216 mutations Expected number of reverse point mutations during (36x109–1) mitoses Calculated in this
study
100 mm2 Minimal size of revertant patch to be clinically recognizable [9], Fig 1
2x106 cells Number of basal keratinocytes required for a revertant patch Calculated in this
study
21 generations Number of generations needed to obtain 2x106 basal keratinocytes Calculated in this
study
14th generation Generation in which revertant cell should occur to obtain revertant patch
of 100 mm2 in generation 35
Calculated in this
study
(Continued)
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effect of BK hierarchy, we assumed an epidermal stem cell:non-stem cell BK ratio of 1:1,000,
based on the review by Strachan and Ghadially [35] and the recent experimental study by
Hirsch et al. [24], who showed that the number of stem cells in their skin transplants was
approximately 1.8×103 per cm2, i.e. approximately 1:1,000 to the number of 2×106 BKs that we
calculated to be present per cm2 skin. This reduces the number of mitoses in which reverse
mutations can occur 1,000-fold. Consequently, the probability P that at least one reverse muta-
tion occurs decreases substantially to 0.19 (as compared to ~1 in the initial model). As the
ratio of cells in the entire body skin vs. a minimal recognizable patch will be left unchanged—
both are reduced 1,000-fold by considering epidermal stem cells—the probability of a recog-
nizable patch will also be left unchanged, i.e. one per ~10,000 patients. In other studies, the
stem cell:non-stem cell BKs ratio has been estimated to be up to 1:10 [36,39], but even if stem
cell numbers in the skin are this high, the probability of the occurrence of recognizable rever-
tant skin patches would not the altered. Hence, integrating stem cells in the model cannot
explain the discrepancy between our clinical observations and the predictions following from
the model.
Third, we used the average human somatic cell mutation rate (1×10−9/nt/mitosis) [27], as
data on the actual mutation rate for BKs are not available, which could be substantially higher.
However, only a ~100,000-fold increase in mutation rate to at least 1×10−4 per nucleotide per
mitosis could explain the occurrence of reverse mutations in the 14th cell generation in every
patient. A recent study performing ultra-deep sequencing of 74 cancer genes in 234 normal
sun-exposed skin biopsies from human eyelids identified 2–6 somatic mutation per megabase
per cell (12,000–36,000 mutations per diploid genome) [40]. We calculated the average num-
ber of somatic mutations to be approximately 105 per BK at adulthood (see Methods section).
Assuming these BKs self-renew monthly to maintain homeostasis for 60 years (720 mitoses),
this would accumulate to approximately 4,425 somatic mutations in BKs in aged skin.
Although the data by Martincorena et al. might thus suggest a higher mutation rate in human
skin than the average human mutation rate, most mutations in their study had a UV-signature,
indicating that such a higher mutation rate is likely attributable to environmental factors
rather than to an intrinsically higher mutation rate. In addition, their results were obtained on
entire epidermis, making it hard to compare to our calculations for BKs only. One could obvi-
ously argue that environmental factors play a major role in the occurrence of reverse muta-
tions in human skin and indeed UV-exposure might induce reverse mutations during life.
Interestingly though, many reverse mutations do not have a UV-signature [11], reducing the
probability that they occur due to environmental factors and supporting our hypothesis that
they should arise early during embryonic development.
Table 2. (Continued)
Quantitative
values
Explanation References
0.0001 Probability P that at least one reverse mutation occurs in the first 14
generations
Calculated in this
study
1/10,000 patients Number of patients predicted to carry clinically recognizable revertant
skin patch
Calculated in this
study
1:1,000 Long term proliferating epidermal stem cells:other basal keratinocytes
ratio
[24,35]
156 Expected number of reverse mutations in epidermal stem cells during
adult life
Calculated in this
study
DEJ, dermo-epidermal junction; REB, recessive epidermolysis bullosa
https://doi.org/10.1371/journal.pone.0192994.t002
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The three points mentioned above may explain a small portion of the discrepancy between
our clinical observations and the predictions from the model. However, another, more likely
explanation why revertant cells grow out to recognizable patches in more-than-expected
patient numbers is that revertant cells possess a strong selective growth advantage over their
non-revertant neighbors, equivalent to what is seen for tumor cells carrying driver mutations
in certain cancer-related genes [40]. If revertant cells are able to survive longer or to go
through more cycles of cell divisions, reverse mutations would be allowed to occur at later
stages of development, when their occurrence is more likely (Fig 2). In hematologic diseases
involving hematopoietic bone marrow stem cells, such a growth advantage is believed to
Fig 1. The smallest revertant patch observed in any of our patients. Photograph of the revertant patch on the dorsal middle finger of patient EB093-01
(deceased) who had generalized intermediate junctional EB due to compound heterozygous COL17A1mutations c.[3676C>T];[4319dup], p.[Arg1226];
[Gly1441Trpfs14] [9]. Note stitched biopsy site for confirmation of type XVII collagen re-expression. The size of the patch was approximately 2 cm2 and it
allowed him to wear a wedding ring. Based on this, we concluded revertant patches should be ~1 cm2 minimum in order to be clinically recognizable.
https://doi.org/10.1371/journal.pone.0192994.g001
Fig 2. Selective growth advantage may explain the occurrence of clinically recognizable revertant patches. (A) Schematic representation of the “bell-shaped” increase
in cell number according to the n = 2y model starting with a single progenitor. In the later generations, the probability of a reverse mutation approaches 1 asymptotically.
However, a reverse mutation that occurs in later generations cannot result in a clinically recognizable patch since the revertant cell cannot go through the required number
of mitoses. (B) We therefore propose that revertant cells have a selective growth advantage, e.g. they possess the ability to go through more generations than their mutant
neighbors. This would allow reverse mutations to occur at later stages and still result in visible patches. Green area: revertant area. Horizontal bar: size of minimal clinically
recognizable patch ( 1 cm2). Gen, generation of cells. NBKs, number of basal keratinocytes. Nsom mut, expected total number of new somatic mutations. Mut/Nt, average
number of mutations per nucleotide. Pno rev, probability of no reverse mutation. P1 rev, probability of at least one reverse mutation.
https://doi.org/10.1371/journal.pone.0192994.g002
Mathematical dissection of revertant mosaicism
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explain the ability to detect reverse mutations and clinical improvement in the first place [41–
46]. As skin is also a continuously self-renewing organ, similar mechanisms may be active in
skin as in the bone marrow. Additionally, growth potential differences between wild-type and
mutant cell lineages have been shown for other diseases like Wiskott-Aldrich syndrome and
neurofibromatosis type I [47,48].
Several arguments support a selective growth advantage of revertant cells in REB skin. First,
revertant patches are not confined to the lines of epidermal development, the lines of Blaschko
[49,50]. Rather, they appear to develop in one Blaschko-line segment and then expand centrif-
ugally into adjacent segments (Fig 3). This observation indicates that reverse mutations occur
when epidermal formation from the Blaschko-lines is completed, i.e. after the end of the 4th
week [37]. This is in line with our conclusion that reverse mutations likely occur in later stages
when the number of epidermal cells has reached the critical amount to allow their occurrence
with a higher probability.
Second, a segmental phenotype due to somatic second-hit mutations has not been reported
in carriers of REB mutations. As there are many more target nucleotides for gene silencing
than for mutation correction, the probability that the wild-type allele is silenced in carriers far
exceeds the probability of reverse mutations in REB patients’ skin [27]. Although carriers may
not all have been meticulously evaluated for small areas of increased skin blistering propensity,
the lack of reports on a segmental phenotype in carriers suggests a significant growth disad-
vantage of cells harboring second-hit mutations.
Third, the expanding revertant patches seen in ichthyosis with confetti due to multiple cor-
rection events in either the KRT1 or KRT10 genes seem to support this hypothesis of a growth
advantage or greater fitness of corrected skin cells over their mutant neighbors [20,21,51,52].
While normal epidermal stem cell units are considered to colonize up to 3 mm in diameter
[35], patches in ichthyosis with confetti due to KRT10 mutations, which first appear around
the age of 6 years, are reported to grow up to 4 cm in diameter [20].
Fig 3. A selective growth advantage of revertant cells is supported by the patterns of the revertant skin patches. (A) Dorsal forearm of an 8-year
old boy (EB134-01) with generalized intermediate junctional EB due to the compound heterozygous COL17A1mutations c.[1260del];
[3496_3497del], p.[Thr421Leufs72];[Ser1166Leufs6] showing a revertant patch (indicated by blue line). (B) The lines of Blaschko on the dorsal
forearm as deduced by Blaschko and Happle [49,50]. (C) The lines of Blaschko projected on the revertant patch on the dorsal forearm of patient
EB134-01. The revertant patch has clearly exceeded the boundaries of the Blaschko lines and has grown into adjacent Blaschko line segments. The
parents of patient EB134-01 have given written informed consent (as outlined in PLOS consent form) to publish this photograph.
https://doi.org/10.1371/journal.pone.0192994.g003
Mathematical dissection of revertant mosaicism
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In our model, the 29th cell generation is the first where the number of mitoses is so high
that more than one reverse mutation is expected to occur. Revertant cells need another 21 gen-
erations to acquire the 2×106 cells of a minimal recognizable patch. They would thus need to
go through at least 15 (21 vs. 6) more generations than their mutant neighbors. Future studies,
perhaps using in vivo imaging techniques in new luminescent and fluorescent genetic animal
models [53], need to clarify whether the revertant growth advantage is indeed of this order of
magnitude. Two different mechanisms may act synergistically in providing the enormous
revertant growth advantage: first, revertant cells may survive longer and, second, may possess
the ability to go through more cell divisions.
Despite their likely growth advantage, the majority of patients do not report expansion of
revertant patches in adulthood, and existing revertant patches do not expand into blistered
areas at their borders. This suggests a limited time frame where the growth advantage can be
exerted, with an end point before adulthood. In a child with Kindler syndrome the revertant
patch expanded relatively to body size until the age of 8 years [18]. This indicates that revertant
patches may have the ability to expand at least until this age. Similar observations have been
made in ichthyosis with confetti (IWC type I) due to KRT10 frameshift mutations, in which
multiple revertant patches arise during childhood and stop expanding before adulthood [20].
In IWC type II caused by KRT1 frameshift mutations, on the other hand, patches usually arise
at a later age [21], indicating that the time window of revertant growth advantage is limited,
but likely varies per gene or even mutation.
Why revertant patches lose their ability to expand further after a certain time point and
are not able to cover the entire body with new, healthy skin and thus cure the disease, is un-
known. In the study by Hirsch et al., exogenously corrected epidermal stem cells were cultured
to produce 0.85 m2 of new epidermis to treat a child with junctional EB due to a homozygous
LAMB3mutation [24]. From this study, it would be expected that corrected stem cells would
have the ability to expand in vivo as well, but this is not what is seen in adult EB patients. In
their review, Colom and Jones state that cells with carcinogenic driver mutations likely have a
short-term advantage over their neighbors, after which their growth is constrained and they
revert to homeostatic behavior. If this is true, a similar mechanism could be active in revertant
cells [54]. Also, age-related changes in the balance between proliferation and differentiation
gene expression programs, for instance due to epigenetic changes at the epidermal differentia-
tion complex locus (1q21) or of proliferation and differentiation gene networks [55–58], could
play a role. Further studies comparing the genomic and epigenomic constitution of revertant
and non-revertant cell lineages could help solve this issue.
In addition to existing patches not expanding further after a certain age, we have neither
witnessed the occurrence of new revertant patches in adult EB patients nor has this been
reported in the literature. Of note, one patient claimed that his revertant patch had occurred
“during life”, but long-term photographic could only confirm the presence of the same patch
throughout follow-up, leaving the question unanswered whether this is a true example of a
new revertant patch occurring later in life [13]. This is particularly remarkable when the occur-
rence of new mutations during adulthood is considered (see Methods section). Analogous to
the calculations used to obtain the frequency of reverse mutations during embryonic develop-
ment until adulthood, it can be estimated that at least 156 new reverse mutations will occur in
epidermal stem cells alone during adult life (Table 2). The lack of new revertant patches arising
during adulthood thus supports the hypothesis that the growth advantage of revertant cells
decreases during life and has a limited time window.
Altogether, our developmental model predicts that REB patients with mutations that are
correctable by single point reversions carry numerous reverse mutations in their skin. Our
observation of revertant patches in at least all the patients with one junctional REB subtype
Mathematical dissection of revertant mosaicism
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seems to form the clinical proof for this prediction. The question remains as to whether it is
also true in other REB subtypes, but this prediction should encourage clinicians to scrutinize
every EB patient for revertant patches (i.e. by asking the patients about the presence of skin
areas that never blister, clinical examination and a ballpoint rub test on suspected patches
[16]), as their presence offers exciting future therapeutic prospects [22,23]. To produce clini-
cally recognizable revertant patches, reverse mutations should, however, arise so early during
embryogenesis that that is expected to occur in only one per ~10,000 patients. We therefore
postulate the “late-but-fitter revertant cell” hypothesis: reverse mutations arise at later stages of
development, but confer a strong selective growth advantage to the revertant cells that drives
their development into revertant patches. Our results indicate that revertant cells should also
be present in the affected tissues in other genetic diseases, provided their stem cell division
numbers are comparable to skin (and bone marrow), like the colorectal tissues [36]. Table 3
shows all genetic conditions in which RM has been identified to date [1,20,21,41,46,59–75].
Next generation sequencing techniques have opened unprecedented opportunities for the
detection of low-grade somatic mosaicism and are perfectly suited to prove whether this
hypothesis is indeed true [76]. If ways can be found to subsequently identify and isolate these
cells, this could offer novel opportunities for revertant cell therapy in other genetic diseases
too.
Methods
Determining the occurrence of reverse mutations in basal keratinocytes
We have used an exponential model in which the total number of basal keratinocytes (BKs), n,
starting with a single embryonic ectodermal progenitor cell, doubles with every generation of
Table 3. Revertant mosaicism in genetic diseases other than epidermolysis bullosa.
Disease OMIM Corrected gene OMIM References
Lesch-Nyhan syndrome 300322 HPRT 308000 [1]
Ichthyosis with confetti, KRT10 609165 KRT10 148080 [20]
Ichthyosis with confetti, KRT1 609165 KRT1 139350 [21]
Fanconi anemia, complementation group A 227650 FANCA 607139 [41]
Dyskeratosis congenita type 1 127550 TERC 602322 [46]
Duchenne muscular dystrophy 310200 DMD 300377 [59]
Myotonic dystrophy 160900 DMPK 605377 [60]
Tyrosinemia type I 276700 FAH 613871 [61]
Bloom syndrome 210900 RECQL3 604610 [62]
Adenosine deaminase deficiency 102700 ADA 608958 [63]
Hereditary motor and sensory neuropathy type 1A 118220 PMP22 duplication 601097 [64]
X-linked severe combined immunodeficiency 300400 IL2RG 308380 [65]
Fanconi anemia, complementation group C 227645 FANCC 613899 [66]
Wiskott-Aldrich syndrome 301000 WAS 300392 [67]
X-linked hypohidrotic ectodermal dysplasia with immunodeficiency 300291 NEMO 300248 [68]
Omenn syndrome 603554 RAG1 179615 [69]
T-cell immunodeficiency 610163 CD3-zeta (CD247) 186780 [70]
Fanconi anemia, complementation group N 610832 PALB2 610355 [71]
Fanconi anemia, complementation group I 609053 FANCI 611360 [72]
Leukocyte adhesion deficiency type 1 116920 ITGB2 600065 [73]
Autosomal recessive severe combined immunodeficiency 600802 JAK3 600173 [74]
Autosomal recessive severe combined immunodeficiency 608971 IL7R 146661 [75]
https://doi.org/10.1371/journal.pone.0192994.t003
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cells, y, according to n = 2y. The total number of BKs, ntotal, in an average adult human body is
a function of the total body dermo-epidermal junction (DEJ) surface SDEJ and the number of
BKs per unit DEJ. The SDEJ is not identical to the human skin surface Sskin, as it is greatly
increased by the presence of rete ridges and dermal papillae. Assuming an average of 6 rete
ridges-dermal papillae complexes per mm skin length (Lskin) with an average height of 0.070
mm [28,29], the DEJ can be described as a sinus function with amplitude 0.035 mm and period
12π (Table 2):
f ðxÞ ¼ 0:035  sinð12  p  xÞ
The exact length of the line described by this sinus, i.e. the actual DEJ length LDEJ, is calcu-
lated by solving the integral of the function (Mathematica, Wolfram Research Inc., Cham-
paign, IL)
LDEJ ¼ FðxÞ ¼
Zb
a
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1þ ð0:42  p  cosð12  p  xÞÞ2
q
dx
Using a = 0 and b = 1 mm Lskin reveals that 1 mm of Lskin corresponds to 1.348 mm LDEJ.
Consequently, since the “finger like appearance” of dermal papillae resembles two interfering
sinus waves [77], 1 mm2 Sskin corresponds to (1.348)2 1.817 mm2 SDEJ. Rete ridges thus theo-
retically expand the dermal-epidermal surface contact by 81.7%.
The number of BKs was measured to be between 15,000 and 20,000 to 30,000 per mm2
skin [33,33]. Assuming that BKs have a circular base of diameter ~10 μm [30] and surface
~78.5 μm2, approximately 12,739 BKs are expected per mm2 SDEJ (1 mm2 SDEJ / 78.5×10−6
mm2 per BK) and 23,146 BKs per mm2 Sskin. Taken together, we decided to use 20,000 BKs per
mm Sskin in further calculations.
Assuming a total human adult body surface of 1.8 m2 (corresponding to 3.3×106 mm2 SDEJ)
the total number of BKs in an adult human body ntotal = 1.8×106 mm2 × 20,000 BKs/mm2 =
36×109. This number is reached in the 35th generation, after a total of 36×109–1 mitoses. Given
a per nucleotide point mutation rate of approximately 1×10−9 per mitosis [26–28] and 6×109
nucleotides per diploid genome [34], ~6 novel point mutations may be expected in the daugh-
ter cell’s genome in each cell division. In the 35th generation of cells, the total expected number
of new point mutations that have occurred in the body’s BKs is approximately 6 × total num-
ber of mitoses = 216×109, indicating that each single nucleotide is expected to be mutated on
average 36 times in the human basal skin layer at adulthood. In total, 3.6×1012 somatic muta-
tions are expected to have accumulated in the body’s BKs at adulthood, which equates to an
average of 105 somatic mutations per BK.
Alteration of one of the nucleotides of a nonsense codon will usually change the nonsense
into a sense codon. If nonsense mutations are present on both alleles, there are therefore 6 tar-
get nucleotides for a reversion, thereby ignoring the small probability that the nonsense codon
will be changed into one of the other two possible nonsense codons. For frame-shift and
splice-site mutations, the number of potential target nucleotides for reversion events are usu-
ally unknown but theoretically numerous. For missense mutations, this number is probably
less than 6. We therefore decided to use the number of 6 target nucleotides of nonsense codons
in our calculations. A larger or smaller number of target nucleotides would not affect the order
of magnitude of the probability of the occurrence of reverse mutations. The probability of a
reverse point mutation per mitosis in case of 6 target nucleotides is thus prev = 6 × 1×10−9 =
6×10−9, The probability that no reverse mutation will occur during the total number of mitoses
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until the 35th generation (Pnot) is
Pnot ¼ ð1   prevÞ
total number of mitoses
¼ ð1   6  10  9Þ
ð3610  9  1Þ
¼ 1:6  10  94
Therefore, the probability P that at least one reverse mutation occurs during these mitoses is
P ¼ 1   Pnot ffi 1
The expected number of reverse mutations in 36×109–1 mitoses is (36×109–1) × 6×10−9 = 216.
Determining the occurrence of clinically recognizable revertant skin
patches
One cm2 of revertant Sskin corresponds to 100 mm2 × 20,000 BKs/mm2 = 2×106 revertant BKs.
According to the 2y model, it takes 21 generations to obtain this number from one single rever-
tant ancestor. This implies that a reverse mutation should have arisen at the latest in the
y = 35–21 = 14th generation, corresponding to a stage of 214 = 16,384 BKs. Considering that in
early embryonic stages rete ridges and dermal papillae are not yet developed [37], the reverse
mutation should have arisen at the embryonic stage where the embryo’s body surface was less
than 2 mm2. For comparison, a 4-week embryo measures approximately 5 mm in length and,
if compared to a cylinder with height = 5 mm and radius = 0.5 mm, its body surface is in the
order of 17 mm2, indicating that a reverse mutation should arise before the 4th week of embry-
onic development in order to give rise to a clinically recognizable revertant skin patch. The
probability Pnot that a reverse mutation does not arise in the first 14 generations is
Pnot ¼ ð1   6  10
  9Þ
ð16;384  1Þ
¼ 0:9999
and the probability P that at least one reverse mutation arises in the first 14 generations is
P ¼ 1   0:9999 ¼ 0:0001
Therefore, a clinically recognizable revertant skin patch is expected once in only ~1/
0.0001 = 10,000 patients.
Determining the occurrence of reverse mutations in epidermal stem cells
during adult life
The number of long-term proliferating epidermal stem cells (ESCs) in an adult human body
was estimated earlier to be approximately 36×106 (total number of BKs / 1,000). Assuming
every ESC divides asymmetrically every month to maintain homeostasis, analogous to the self-
renewal time of the entire epidermis, every ESC would go through 12 × 60 = 720 mitoses until
the age of 78 years, totaling to 720 mitoses × 36×106 ESCs = 26×109 mitoses in the entire
human body. Assuming the daughter cells would remain as ESCs in the basal layer, 26×109
mitoses × 6 mutations/mitosis = 156×109 new somatic mutations are expected to accumulate,
equivalent to 26 mutations per nucleotide (156×10 9 mutations / 6×109 nucleotides per diploid
genome). As there are 6 candidate nucleotides for reverse mutations, 6 × 26 = 156 reverse
mutations are expected in ESCs during adult life.
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